693285-67-5

Usage

Uses

Used in Pharmaceutical Industry:
[5-(1-METHYLETHYL)-1H-INDAZOL-4-YL] BORONIC ACID is used as a building block for the development of new pharmaceuticals. Its unique structure allows it to form stable complexes with diol-containing molecules, which can be exploited in the design of drugs targeting specific biological receptors or enzymes.
Used in Agrochemical Industry:
In the agrochemical industry, [5-(1-METHYLETHYL)-1H-INDAZOL-4-YL] BORONIC ACID is used as a key intermediate in the synthesis of novel agrochemicals. Its ability to complex with biological targets can be utilized to develop compounds with improved activity and selectivity against pests and diseases.
Used in Materials Science:
[5-(1-METHYLETHYL)-1H-INDAZOL-4-YL] BORONIC ACID is used as a component in the development of advanced materials. Its potential reactivity and ability to form complexes with specific targets can be harnessed to create materials with tailored properties for various applications, such as sensors, catalysts, or advanced polymers.
Further research and investigations are needed to explore the full range of applications and potential uses of [5-(1-METHYLETHYL)-1H-INDAZOL-4-YL] BORONIC ACID in these and other fields.

Upstream product

• 1252572-35-2 2-isopropyl-6-methyl-5-nitro-bromobenzene 
• 693285-68-6 3-bromo-4-isopropyl-2-methyl-aniline 
• 65232-56-6 2-isopropyl-6-methyl-bromobenzene 
• 610796-21-9 4-bromo-5-isopropyl-1H-indazole 

Relevant academic research and scientific papers

3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES

The present invention provides compounds of Formula (I) or (II) salt form or prodrug thereof, wherein variables are defined herein, that are modulators of metalloproteases such as matrix metalloproteases (MMPs) and ADAMs. The compounds or compositions described herein can be used to treat diseases associated with metalloprotease activity including, for example, arthritis, cancer, cardiovascular disorders, skin disorders, inflammation or allergic conditions.

1-ARYL-4-SUBSTITUTED ISOQUINOLINES

1-Aryl-4-substituted isoquinolines analogues of Formula (I) and Formula (II) are provided, as follows : wherein R1, R2, R3, R8, R9, A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula (I) and (II) bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compositions compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled 1-aryl-4-substituted isoquinolines, which are useful as probes for the localization of C5a receptors.

4,5-DISUBSTITUTED-2-ARYL PYRIMIDINES

4,5-disubstituted-2-arylpyrimidines of Formula (I) and Formula (II) are provided: wherein R1, R2, R3, R8, R9, A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula I and II bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse activity at C5a receptors. The present invention also relates to pharmaceutical compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled 4,5-disubstituted-2-arylpyrimidines, which are useful as probes for the localization of C5a receptors.

3-SUBSTITUTED-6-ARYL PYRIDINES

3-substituted-6-aryl pyridines of Formula (I) are provided: Formula (I) wherein R1, R2, R3, R8, R9, A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula (I) bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled 3-substituted-6-aryl pyridines, which are useful as probes for the localization of C5a receptors.